research use only

Amifostine trihydrate

Name: Amifostine trihydrate
Brand: Selleck Chemicals
SKU: S4298
Availability: InStock
Rating: 5 (7 reviews)

Cat.No.S4298

Amifostine trihydrate(WR2721 trihydrate) is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin.

Amifostine trihydrate Chemical Structure

Quality Control

Batch: Purity: >97%

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS/MSDS

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS/MSDS

Related Targets	PROTAC Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin Selection Antibiotics for Transfected Cell Antibiotics for Mammalian Cell Culture ADC Linker Molecular Glues Hydrotropic Agents Antibiotics for Plant Cell Culture
Other Others Inhibitors	Furimazine (PBI 3939) Guanidinoacetic acid Blebbistatin Polybrene (Hexadimethrine Bromide) Silibinin (NSC 651520) Palmitic acid Carbazochrome sodium sulfonate (AC-17) 4-Methylumbelliferone (4-MU) Sesamin Osthole

Solubility

In vitro
Batch:

Water : 54 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	saline Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	10.000mg/ml (37.28mM)	Taking the 1 mL working solution as an example, add 10 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	268.27	Formula	C₅H₁₅N₂O₃PS.3H₂O	Storage (From the date of receipt)	4°C, protect from light, stored under nitrogen, powder
CAS No.	112901-68-5	Download SDF		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms	WR2721 trihydrate			SMILES	C(CN)CNCCSP(=O)(O)O.O.O.O

Read more about storage stability CAS number SMILES

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2023-07-05)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00003927	COMPLETED	Breast Cancer	City of Hope Medical Center	1999-05-18	PHASE1
NCT00217438	COMPLETED	Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma	Fred Hutchinson Cancer Center	2005-07	PHASE3
NCT00040365	COMPLETED	Prostatic Neoplasms	National Cancer Institute (NCI)	2002-06	PHASE2
NCT00503776	TERMINATED	Dysphagia; Head and Neck Cancer; Mucositis; Xerostomia	Vanderbilt-Ingram Cancer Center	2006-01	PHASE2
NCT00058071	COMPLETED	Gestational Trophoblastic Tumor; Neurotoxicity; Peripheral Neuropathy; Unspecified Adult Solid Tumor, Protocol Specific	Gynecologic Oncology Group	2003-03	PHASE3
NCT00003994	COMPLETED	Childhood Hepatoblastoma; Recurrent Childhood Liver Cancer; Stage I Childhood Liver Cancer	Children's Oncology Group	1999-03	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):